Back to the main directory
EarningsReview / Equity
- A clearer path forward by BNP Paribas Exane
- Prosegur Cash - 4Q22 Results: FX evolution is a drag but FCF generation remains strong; we reiterate Buy by JB Capital Markets
- Good trends in CASH by BNP Paribas Exane
- Saying the Right Things by BNP Paribas Exane
- Mixed 2022, Positive 2023 outlook by BNP Paribas Exane
- Itaú BBA on Marcopolo: Strong 4Q22, Positive Surprises Across the Board by Itau
- Aena - 4Q22 Review: Positive traffic outlook but we stay Neutral by JB Capital Markets
- Itaú BBA on AURA MINERALS: 4Q22 Conference Call Highlights by Itau
- Itaú BBA on Petrobras: MME Nominates Petrobras Board of Directors by Itau
- In line results, admittedly weaker mix though by BNP Paribas Exane
- The Law Debenture Corporation - Standing the test by Edison Investment Research
- Jyske Bank - How to determine your own faith in a year by Danske Bank Equity Research
- REDEIA: FY2022 RESULTS (ANÁLISIS BANCO SABADELL) by Sabadell
- SOLARIA: RDOS. 2022 (ANÁLISIS BANCO SABADELL) by Sabadell
- Strong results, above expectations by BNP Paribas Exane
- Strong 2023 outlook: even sunnier holidays ahead by BNP Paribas Exane
- Ripping the band-aid off in two steps is harder than one by BNP Paribas Exane
- No band-aid needed, just steady growth by BNP Paribas Exane
- Måsøval (Buy, TP: NOK40.00) - Soft Q4, but looking good for Q2 by DnB Markets
- Vicore Pharma (Buy, TP: SEK70.00) - Waiting for phase IIb trial to start by DnB Markets
- Physitrack (Buy, TP: SEK40.00) - FCF break-even needed by DnB Markets
- Malaysia Airports Holding (MAHB MK) by HSBC
- Itaú BBA on Falabella: Very Negative 4Q22, Worrisome Leverage by Itau
- Itaú BBA on Randon: In-Line 4Q22, Mind the Challenges in 2023 by Itau
- Kap Industrial Holdings (KAP SJ) by HSBC